Prophylaxis of postmenopausal osteoporosis
Adult: As ossein-hydroxyapatite compound: 1660 mg bid.
Indications and Dosage
Oral
Prophylaxis of postmenopausal osteoporosis Adult: As ossein-hydroxyapatite compound: 1660 mg bid.
|
Contraindications
Hypersensitivity. Children <6 yr. Prolonged immobilization accompanied by hypercalciuria.
|
Special Precautions
Monitor serum calcium level during treatment. To be taken with vitamin D for maximal benefit. Caution when used in renally impaired patients.
|
Adverse Reactions
Risk of hypercalciuria.
|
Drug Interactions
Biphosphonates may increase the osteoconductive and regenerative properties of hydroxyapatite when used together.
|
Action
Description:
Mechanism of Action: Hydroxyapatite is a natural mineral with composition similar to that of the mineral in bone. It is prepared from bovine bone and contains calcium, phosphate, trace elements, fluoride and other ions, proteins and glycosaminoglycans. |
MIMS Class
|